Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a third-quarter 2025 adjusted net profit of 235 billion Japanese yen (approximately $1.53 billion).
The company reported earnings per American Depositary Share (EPADS) of 47 cents, missing analyst expectations of 55 cents. However, in yen, earnings per share increased 12.4% (+5.4% at CER) to 149 yen.
Total sales for the quarter amounted to $7.60 billion (1.192 trillion yen), missing the consensus estimates of $8.53 billion. Sales were 4.2%, and at constant currency, sales fell marginally by 0.6%.
The decline was primarily due to a decrease in Neuroscience revenue, mainly from the continued impact of generic erosion of Vyvanse for attention deficit hyperactivity disorder (ADHD).
Third quarter Neuroscience sales fell 23.6% to 108.4 billion yen, vaccine sales almost doubled to 23.3 billion yen, and cancer drug sales were up …